WO2023068423A1 - Composition de médicament anticancéreux complexe utilisant la photoréactivité et son procédé de préparation - Google Patents
Composition de médicament anticancéreux complexe utilisant la photoréactivité et son procédé de préparation Download PDFInfo
- Publication number
- WO2023068423A1 WO2023068423A1 PCT/KR2021/015653 KR2021015653W WO2023068423A1 WO 2023068423 A1 WO2023068423 A1 WO 2023068423A1 KR 2021015653 W KR2021015653 W KR 2021015653W WO 2023068423 A1 WO2023068423 A1 WO 2023068423A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- core
- photosensitizer
- group
- agent composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 239000002246 antineoplastic agent Substances 0.000 title claims description 57
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title abstract description 63
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 92
- 239000000126 substance Substances 0.000 claims abstract description 44
- 230000001093 anti-cancer Effects 0.000 claims abstract description 25
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 20
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 20
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 15
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 15
- 239000000693 micelle Substances 0.000 claims description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 43
- 230000002285 radioactive effect Effects 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 17
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 229910052740 iodine Inorganic materials 0.000 claims description 15
- 239000011630 iodine Substances 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 11
- 229960003105 metformin Drugs 0.000 claims description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 9
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 claims description 8
- XOBIGRNRXCAMJQ-UHFFFAOYSA-N 3-(dipyridin-2-ylmethylideneamino)-1,1-dimethylthiourea Chemical compound C=1C=CC=NC=1C(=NNC(=S)N(C)C)C1=CC=CC=N1 XOBIGRNRXCAMJQ-UHFFFAOYSA-N 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 claims description 8
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 229910052723 transition metal Inorganic materials 0.000 claims description 8
- 150000003624 transition metals Chemical class 0.000 claims description 8
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 7
- 229940117893 apigenin Drugs 0.000 claims description 7
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 7
- 235000008714 apigenin Nutrition 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- ZEGDFCCYTFPECB-UHFFFAOYSA-N 2,3-dimethoxynaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(OC)=C(OC)C(=O)C2=C1 ZEGDFCCYTFPECB-UHFFFAOYSA-N 0.000 claims description 4
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 claims description 4
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 claims description 4
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- VABYUUZNAVQNPG-UHFFFAOYSA-N Piperlongumine Natural products COC1=C(OC)C(OC)=CC(C=CC(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-UHFFFAOYSA-N 0.000 claims description 4
- WHAAPCGHVWVUEX-UHFFFAOYSA-N Piperlonguminine Natural products CC(C)CNC(=O)C=CC=CC1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-UHFFFAOYSA-N 0.000 claims description 4
- VABYUUZNAVQNPG-BQYQJAHWSA-N Piplartine Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-BQYQJAHWSA-N 0.000 claims description 4
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 claims description 4
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 claims description 4
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 4
- 229960004991 artesunate Drugs 0.000 claims description 4
- 229910052793 cadmium Inorganic materials 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 4
- 229940099500 cystamine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 claims description 4
- 229940080817 rotenone Drugs 0.000 claims description 4
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 claims description 4
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 claims description 4
- IMUBGIOLZQTIGI-UHFFFAOYSA-N 2-allyl-1-hydroxy-9,10-anthraquinone Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC(CC=C)=C2O IMUBGIOLZQTIGI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 description 62
- 206010028980 Neoplasm Diseases 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 25
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 238000002428 photodynamic therapy Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 229920002994 synthetic fiber Polymers 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 150000004035 chlorins Chemical class 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- BSUBVJVWWWPFAA-VWZUUSKUSA-N (20R,24S,26S)-7-ethenyl-12-ethyl-19,20-dihydroxy-6,11,26,27-tetramethyl-2,16,28,29-tetrazaheptacyclo[15.7.1.13,24.15,8.110,13.115,18.020,25]nonacosa-1(25),3,5(29),6,8,10(28),11,13,15(27),16,18-undecaen-21-one Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C([C@]5(C(=O)CC[C@H]6[C@@H](C(=CC7=NC(=C2)C(=C7C)C=C)NC6=C5C4=N3)C)O)O)C)C BSUBVJVWWWPFAA-VWZUUSKUSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- IQMLCMKMSBMMGR-UHFFFAOYSA-N (4-iodophenyl)hydrazine Chemical compound NNC1=CC=C(I)C=C1 IQMLCMKMSBMMGR-UHFFFAOYSA-N 0.000 description 1
- BTLXPCBPYBNQNR-UHFFFAOYSA-N 1-hydroxyanthraquinone Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2O BTLXPCBPYBNQNR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- -1 bonnelin Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- APBBAQCENVXUHL-UHFFFAOYSA-N n,n-diethylethanamine;2,2,2-trifluoroacetic acid Chemical compound CCN(CC)CC.OC(=O)C(F)(F)F APBBAQCENVXUHL-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to an anticancer composition comprising a photosensitizer and a method for preparing the same.
- Photodynamic therapy refers to a technique for treating incurable diseases such as cancer without surgery using a photosensitizer, and has been attempted since around 1400 BC and actively researched in the early 20th century.
- PDT used for cancer treatment irradiates light to a photosensitive agent, thereby changing oxygen molecules (O 2 ) into singlet oxygen, creating new radicals, or creating new chemical species to cancer cells. It is to selectively kill only.
- the photosensitizers used at this time include porphyrin derivatives, which are first-generation photosensitizers, and chlorin, bacteriochlorin, and phthalocyanine, which are second-generation photosensitizers.
- Photosensitizers are classified according to their chemical structure and physicochemical properties. From the 1st generation to the 2nd generation, the absorption wavelength band is longer and the time to be excreted outside the body is faster. Chlorin derivatives have several advantages, such as a low phototoxicity rate due to rapid excretion in vitro and a large number of substituents capable of chemical change.
- chlorin compounds such as bonnelin, tolyporphin, and chlorophyllone A have been synthesized, but since the synthesis and extraction of these compounds are very difficult, the synthesis of new photosensitizers has started. It is difficult to use it as a material or to use it as a photosensitizer itself.
- each radioactive isotope has its own half-life.
- radioactive iodine iodine-131
- Cu-67 Copper-67
- each of these side effects are not severe, mild side effects may persist for more than 6 months.
- a synthetic material of a radioactive isotope with a relatively long half-life and a photosensitizer with a half-life as short as 1 to 2 days is expected to be a combination that can improve anticancer efficacy and minimize side effects by combining radiotherapy and photodynamic therapy. .
- Radioactive iodine (iodine-131) was attempted before and after World War II.
- Thyroid hormone is produced by thyroid tissue in the human body, and iodine is an essential element for making thyroid hormone.
- radioactive iodine When radioactive iodine is injected into the human body, it accumulates in the thyroid tissue and is detected with a Geiger Counter or gamma camera to analyze the presence, location and size of thyroid cancer. Since radioactive iodine emits beta rays that can kill cancer cells as well as gamma rays detected by gamma camera images, it can be applied to treat thyroid cancer. Therefore, because of the characteristics of radiation emitted from radioactive iodine, imaging diagnosis and treatment of thyroid cancer is possible.
- the radioactive isotope Cu-67 is an emitter of beta rays and gamma rays, and the average energy of beta rays and gamma rays is 141keV and 157keV, respectively, and has nuclear characteristics suitable for in vivo diagnosis and treatment of malignant tumors of 2 mm in size.
- the synthetic material of a radioactive isotope for radiotherapy and a photosensitizer for photodynamic therapy has a half-life while simultaneously diagnosing and treating cancer. It is thought that it will be able to meet the needs of the times to minimize side effects by appropriately adjusting.
- cancer patients receive radiation therapy to remove cancer cells that are difficult to operate or remain after surgery.
- the energy from the radiation generates 'active oxygen' around the cancer cells, destroying the DNA of the cancer cells.
- cancer cells that are relatively distant from the blood vessels because they cannot supply enough oxygen and nutrients to the entire cell survive at a high rate. They have resistance to radiation irradiation that is 100 times greater than normal cells, as well as 'strong toughness' that makes it difficult for anti-cancer drugs to penetrate cells.
- photodynamic therapy is attracting attention as a treatment to kill cancer cells in hypoxic conditions, but due to its low selectivity, it causes damage to surrounding normal tissues.
- PSs photosensitizers
- ROS_iA reactive oxygen species inducing amplifier synthetic material
- Patent Document 1 Korea Patent Registration No. 10-0912446
- An object of the present invention is to provide an anticancer drug composition showing high anticancer and anti-inflammatory activity and a method for preparing the same.
- the anticancer drug composition according to one embodiment of the present invention is in the form of micelles including a core and a shell, the core includes a photosensitizer represented by Formula 1 below, and the shell is bovine serum albumin ( Bovine serum albumin (BSA) or human serum albumin (HSA) may be included.
- BSA bovine serum albumin
- HSA human serum albumin
- R 1 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, an alkylene group having 1 to 3 carbon atoms, an aldehyde group, an alkylhydroxyl group having 1 to 3 carbon atoms, or ego,
- R 4 is a radioactive iodine isotope or an iodinated phenyl group containing a radioactive iodine isotope
- M is a radioactive isotope containing copper-67 (Cu-67),
- x is 0 or 1
- L is cystamine or hydrazine
- n 0 or 1
- R 2 is a hydroxyl group; hydrazide group; an alkoxy group including at least one selected from the group consisting of a methoxy group, an ethoxy group, and combinations thereof; an anticancer component or a derivative thereof comprising at least one selected from the group consisting of paclitaxel, docetaxel, doxorubicin, and combinations thereof; or Apigenin, Metformin, LY294002, Paraquat, Antimycin-A, Salicylhydroxamic acid, Alloxan, Rotenone , Pyocyanin, Patulin, Piperlongumine, DMNQ, Artesunate, N -[6-(4-Chlorophenoxy)hexyl]- N' - cyano- N'' -4-pyridinylguanidine (CHS-828), 2-(Di-2-pyridinylmethylene)-N,N-dimethyl-hydrazinecarbothioamide (Dp44mT), 2-All
- the transition metal includes at least one selected from the group consisting of Cu, Fe, Cd, Co, and combinations thereof,
- the R 3 is a hydrogen atom or -COOCH 3 .
- the core may include a photosensitizer represented by Chemical Formula 2 below.
- the core may include a photosensitizer represented by Chemical Formula 3 below.
- the core may include a photosensitizer represented by Chemical Formula 4 below.
- the core may include a photosensitizer represented by Chemical Formula 5 below.
- the core may include a photosensitizer represented by Chemical Formula 6 below.
- the core may include a photosensitizer represented by Chemical Formula 7 below.
- the core may include a photosensitizer represented by Chemical Formula 8 below.
- the core may include a photosensitizer represented by Formula 8b below.
- the core may include a photosensitizer represented by Chemical Formula 8c.
- the core may include a photosensitizer represented by Chemical Formula 9 below.
- the core may include a photosensitizer represented by Chemical Formula 10 below.
- the core may include a photosensitizer represented by Chemical Formula 11 below.
- the core may include a photosensitizer represented by Chemical Formula 12 below.
- the core may include a photosensitizer represented by Chemical Formula 13 below.
- the shell may be attached to the surface of the core through a hydrophobic bond.
- the average particle size of the micelles may be 50 nm to 300 nm.
- the micelle may have a polydispersity index (PDI) of 0.1 to 0.3.
- PDI polydispersity index
- the method for preparing an anticancer drug composition according to the present invention includes preparing an aqueous solution containing bovine serum albumin or human serum albumin; Obtaining a mixture by adding dropwise a photosensitizer solution to the aqueous solution and mixing; and concentrating the mixture under reduced pressure to prepare micelles, wherein the micelles include a core containing the photosensitizer; And it may include a shell containing the bovine serum albumin or human serum albumin.
- the photosensitizer solution includes a photosensitizer and a solvent
- the solvent may include at least one selected from the group consisting of methanol, ethanol, acetone, hexane, ethyl acetate, dichloromethane, tetrahydrofuran, and combinations thereof can
- the preparation method may further include freeze-drying the micelles.
- the micelles may contain additional drugs.
- the anticancer drug composition in the form of micelles according to the present invention exhibits high anticancer and anti-inflammatory activities.
- the anticancer drug composition in the form of micelles according to the present invention is obtained by attaching a shell made of an amino acid-based compound with high water solubility to a core containing a photosensitizer, and is easy to develop as a drug due to its high solubility in water.
- FIG 1 shows the form of an anticancer agent composition according to the present invention.
- 2a is a result of analyzing the compound according to Formula 8b obtained in Preparation Example 1 by nuclear magnetic resonance (NMR).
- 2b is a result of analyzing the compound according to Formula 8b obtained in Preparation Example 1 by fast atomic impact mass spectrometry (Fertility Awareness Based Methods, FABMs).
- Figure 2c is the result of analyzing the compound according to formula 8b obtained in Preparation Example 1 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- FIG. 3a is a result of analyzing the compound according to Formula 8c obtained in Preparation Example 2 by fast atom impact mass spectrometry (FABMs).
- Figure 3b is the result of analyzing the compound according to formula 8c obtained in Preparation Example 2 by ultraviolet visible spectroscopy (UV-Vis).
- FIG. 4a is a result of analyzing the compound according to Formula 11 obtained in Preparation Example 3 by nuclear magnetic resonance spectroscopy (NMR).
- Figure 4b is a result of analyzing the compound according to Formula 11 obtained in Preparation Example 3 by a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS).
- Figure 4c is the result of analyzing the compound according to Formula 11 obtained in Preparation Example 3 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- FIG. 5a is a result of analyzing the compound according to Formula 12 obtained in Preparation Example 4 by nuclear magnetic resonance spectroscopy (NMR).
- Figure 5b is a result of analyzing the compound according to Formula 12 obtained in Preparation Example 4 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- 6a is a result of analyzing the compound according to Formula 13 obtained in Preparation Example 5 by nuclear magnetic resonance spectroscopy (NMR).
- 6b is a result of analyzing the compound according to Formula 13 obtained in Preparation Example 5 by a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS).
- Figure 6c is the result of analyzing the compound according to Formula 13 obtained in Preparation Example 5 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- 7a is a result of analyzing micelles containing the anticancer drug composition Formula 3 according to Preparation Example 6 with a scanning electron microscope (SEM).
- 7B is a result of analyzing the particle size of micelles containing the anticancer drug composition Formula 3 according to Preparation Example 6.
- 8a is a result of analyzing micelles containing the anticancer drug composition Formula 11 according to Preparation Example 6 with a scanning electron microscope (SEM).
- 8B is a result of analyzing the particle size of micelles containing the anticancer drug composition Formula 11 according to Preparation Example 6.
- 9a is a result of analyzing micelles containing the anticancer drug composition Formula 13 according to Preparation Example 6 with a scanning electron microscope (SEM).
- 9B is a result of analyzing the particle size of micelles containing the anticancer drug composition Formula 13 according to Preparation Example 6.
- 10a is a result of analyzing micelles including anticancer drug composition formula 13 and metformin according to Preparation Examples 6 and 7 with a scanning electron microscope (SEM).
- 10B is a result of analyzing the particle size of micelles containing the anticancer drug composition Chemical Formula 13 and Metformin according to Preparation Examples 6 and 7.
- the anticancer agent composition may be in a micelle form including a core 10 and a shell 20.
- the core 10 may include a photosensitizer represented by Chemical Formula 1 below.
- the photosensitizer is a chlorine derivative, and the present invention is characterized by maximizing anticancer and anti-inflammatory activity by introducing various substituents thereto.
- R 1 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, an alkylene group having 1 to 3 carbon atoms, an aldehyde group, an alkylhydroxyl group having 1 to 3 carbon atoms, or can be
- R 4 is an iodine atom or can be
- the M may be a radioactive isotope including copper-67 (Cu-67).
- the x may be 0 or 1.
- the L may be cystamine or hydrazine.
- the n may be 0 or 1.
- R 2 is a hydroxyl group; hydrazide group; an alkoxy group including at least one selected from the group consisting of a methoxy group, an ethoxy group, and combinations thereof; an anticancer component or a derivative thereof comprising at least one selected from the group consisting of paclitaxel, docetaxel, doxorubicin, and combinations thereof; or Apigenin, Metformin, LY294002, Paraquat, Antimycin-A, Salicylhydroxamic acid, Alloxan, Rotenone , Pyocyanin, Patulin, Piperlongumine, DMNQ, Artesunate, N -[6-(4-Chlorophenoxy)hexyl]- N' - cyano- N'' -4-pyridinylguanidine (CHS-828), 2-(Di-2-pyridinylmethylene)-N,N-dimethyl-hydrazinecarbothioamide (Dp44mT), 2-All
- the R 3 may be a hydrogen atom or -COOCH 3 .
- the photosensitizer may include an anticancer component or a derivative thereof including at least one selected from the group consisting of paclitaxel, docetaxel, doxorubicin, and combinations thereof at the R 2 position.
- the anti-cancer component or a derivative thereof is a compound targeting cancer tissue, and is intended to enhance the anti-cancer and anti-inflammatory effects of the anti-cancer composition.
- the photosensitizer is apigenin, metformin, LY294002, paraquat, antimycin-A, salicylhydroxamic acid, alloxan at the R 2 position ( Alloxan), Rotenone, Pyocyanin, Patulin, Piperlongumine, DMNQ, Artesunate, N- [6-(4- Chlorophenoxy)hexyl]- N' -cyano- N'' -4-pyridinylguanidine (CHS-828), 2-(Di-2-pyridinylmethylene)-N,N-dimethyl-hydrazinecarbothioamide (Dp44mT), 2-Allyl-1- It may include a reactive oxygen species inducing amplifier including at least one selected from the group consisting of hydroxy-9,10-anthraquinone (R162), transition metals, and combinations thereof.
- the transition metal may include Cu, Fe, Cd, Co, and the like.
- the reactive oxygen species-induced amplifying agent is used alone, it is inevitable to treat at a high dose.
- the reactive oxygen species induction enhancer when introduced as a substituent of the chlorine derivative, the photosensitizer can generate more active oxygen and reduce its processing capacity.
- the treatment time can be significantly reduced compared to the case of using the chlorine derivative alone.
- the L means a linker.
- the linker may include cystamine or hydrazine.
- the linker includes one that can be cleaved under weakly acidic conditions or UV-Vis light. Since the weakly acidic condition is similar to the environment in cancer cells, the anticancer component and the active oxygen species enhancer can be specifically accumulated in cancer cells.
- the photosensitizer may be labeled with a radioactive iodine isotope.
- the radioactive iodine isotope itself or in the form of an iodinated phenyl group may be substituted at the R 4 position.
- the radioactive iodine isotope may include at least one selected from the group consisting of 123 I, 124 I, 125 I, 131 I, and combinations thereof.
- Cancer diagnosis and photodynamic therapy can be performed more easily by labeling the photosensitizer with the radioactive iodine isotope.
- the photosensitizer may be a radioactive isotope including copper-67 (Cu-67) coordinated. Since copper-67 is a radioactive isotope that emits both gamma rays for diagnosis and beta rays for treatment, cancer diagnosis and photodynamic therapy can be more easily performed by using the photosensitizer according to the present invention.
- cancer diagnosis efficiency can be increased with a smaller amount.
- the photosensitizer may include a compound represented by Chemical Formula 2 below.
- the photosensitizer may include a compound represented by Chemical Formula 3 below.
- the photosensitizer may include a compound represented by Chemical Formula 4 below.
- the photosensitizer may include a compound represented by Chemical Formula 5 below.
- the photosensitizer may include a compound represented by Chemical Formula 6 below.
- the photosensitizer may include a compound represented by Chemical Formula 7 below.
- the photosensitizer may include a compound represented by Chemical Formula 8a below.
- the photosensitizer may include a compound represented by Chemical Formula 8b below.
- 2a is a result of analyzing the compound according to Formula 8b obtained in Preparation Example 1 by nuclear magnetic resonance (NMR).
- 2b is a result of analyzing the compound according to Formula 8b obtained in Preparation Example 1 by fast atomic impact mass spectrometry (Fertility Awareness Based Methods, FABMs).
- Figure 2c is the result of analyzing the compound according to formula 8b obtained in Preparation Example 1 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- the photosensitizer may include a compound represented by Chemical Formula 8c below.
- the compound according to Compound 8a and copper acetate (Cu(II)(OAc) 2 ) were dissolved in a mixed solution of methanol and dichloromethane, and then stirred for 6 hours under nitrogen and dark conditions. Dichloromethane and water are added to the reactants to obtain an organic layer. The obtained product is dried and purified by silica column chromatography to obtain a compound according to Formula 8c.
- FIG. 3a is a result of analyzing the compound according to Formula 8c obtained in Preparation Example 2 by fast atom impact mass spectrometry (FABMs).
- Figure 3b is the result of analyzing the compound according to formula 8c obtained in Preparation Example 2 by ultraviolet visible spectroscopy (UV-Vis).
- the photosensitizer may include a compound represented by Chemical Formula 9 below.
- the photosensitizer may include a compound represented by Chemical Formula 10 below.
- the photosensitizer may include a compound represented by Formula 11 below.
- paclitaxel paclitaxel
- dicyclohexylcarbodiimide N, N'-Dicyclohexylcarbodiimide, DCC
- 4-dimethylaminopyridine 4-Dimethylaminopyridine, DMAP
- FIG. 4a is a result of analyzing the compound according to Formula 11 obtained in Preparation Example 3 by nuclear magnetic resonance spectroscopy (NMR).
- Figure 4b is a result of analyzing the compound according to Formula 11 obtained in Preparation Example 3 by a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS).
- Figure 4c is the result of analyzing the compound according to Formula 11 obtained in Preparation Example 3 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- the photosensitizer may include a compound represented by Chemical Formula 12 below.
- FIG. 5a is a result of analyzing the compound according to Formula 12 obtained in Preparation Example 4 by nuclear magnetic resonance spectroscopy (NMR).
- Figure 5b is a result of analyzing the compound according to Formula 12 obtained in Preparation Example 4 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- the photosensitizer may include a compound represented by Chemical Formula 13 below.
- 6a is a result of analyzing the compound according to Formula 13 obtained in Preparation Example 5 by nuclear magnetic resonance spectroscopy (NMR).
- 6b is a result of analyzing the compound according to Formula 13 obtained in Preparation Example 5 by a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS).
- Figure 6c is the result of analyzing the compound according to Formula 13 obtained in Preparation Example 5 by ultraviolet visible spectrophotometer (UV-Visible Spectrophotometer, UV-Vis).
- the shell may contain bovine serum albumin (BSA) or human serum albumin (HAS).
- BSA bovine serum albumin
- HAS human serum albumin
- the shell is a configuration for increasing the water solubility of the anticancer composition.
- the photosensitizer has low water solubility and high anticancer activity.
- the bovine serum albumin or human serum albumin has low anticancer activity and high water solubility. Therefore, in the present invention, the photosensitizer is coated with bovine serum albumin or human serum albumin to take advantage of only the advantages of the two materials.
- the anticancer composition is easy to develop into a drug because its solubility in water is increased by the shell containing bovine serum albumin or human serum albumin.
- the shell may be attached to the surface of the core including the photosensitizer through a hydrophobic bond.
- the micelles including the core and the shell may have an average particle size of 50 nm to 300 nm.
- the average particle size may mean the diameter of the micelle particle.
- the micelle may have a polydispersity index (PDI) of 0.1 to 0.3.
- the method for preparing an anticancer drug composition according to the present invention includes preparing an aqueous solution containing bovine serum albumin or human serum albumin, adding a photosensitizer solution to the aqueous solution and mixing to obtain a mixture, and concentrating the mixture under reduced pressure to obtain micelles. It may include a step of preparing, and a step of preparing metformin-added bovine serum nanoparticles (Met-BSA NPs) by stirring metformin with micelles.
- Method-BSA NPs metformin-added bovine serum nanoparticles
- the photosensitizer solution may be one in which the aforementioned photosensitizer is dissolved in a solvent.
- the solvent is not particularly limited, but examples thereof include polar solvents such as methanol, ethanol, acetone, and tetrahydrofuran; or a non-polar solvent such as hexane, ethyl acetate, or dichloromethane.
- the solvent may preferably include tetrahydrofuran.
- the photosensitizer solution may be added in a dropwise manner, but is not limited thereto.
- an anticancer drug composition in the form of a micelle containing the aforementioned core and shell can be obtained.
- unreacted substances, impurities, and the like may be removed through sonication, centrifugation, and the like for the anticancer drug composition.
- the manufacturing method may further include freeze-drying the purified anticancer drug composition.
- the anticancer agent composition can be freeze-dried to make it into a form suitable for distribution and storage.
- a bovine serum albumin micelle containing an anticancer drug composition can be prepared as follows.
- aqueous solution of bovine serum albumin dissolved in an aqueous solvent was prepared, and a photosensitizer solution was prepared by dissolving the compounds represented by Chemical Formulas 1 to 13 in tetrahydrofuran, respectively.
- the photosensitizer solution was added in a dropwise manner.
- Tetrahydrofuran was gradually removed using a vacuum concentrator to obtain an anticancer agent composition composed of a core containing each compound and a shell containing the bovine serum albumin.
- the anticancer drug composition was treated with ultrasonic waves, and the remaining material was removed using a centrifugal separator. The product was freeze-dried.
- 7a is a result of analyzing micelles containing the anticancer drug composition Formula 3 according to Preparation Example 6 with a scanning electron microscope (SEM).
- 7B is a result of analyzing the particle size of micelles containing the anticancer drug composition Formula 3 according to Preparation Example 6.
- the average particle size of the anticancer composition is about 140.8 nm, and the polydispersity index (PDI) is 0.168.
- 8a is a result of analyzing micelles containing the anticancer drug composition Formula 11 according to Preparation Example 6 with a scanning electron microscope (SEM).
- 8B is a result of analyzing the particle size of micelles containing the anticancer drug composition Formula 11 according to Preparation Example 6. Referring to this, it can be seen that the average particle size of the anticancer composition is about 191.3 nm, and the polydispersity index (PDI) is 0.261.
- SEM scanning electron microscope
- 9a is a result of analyzing micelles containing the anticancer drug composition Formula 13 according to Preparation Example 6 with a scanning electron microscope (SEM).
- 9B is a result of analyzing the particle size of micelles containing the anticancer drug composition Formula 13 according to Preparation Example 6. Referring to this, it can be seen that the average particle size of the anticancer agent composition is about 182.8 nm, and the polydispersity index (PDI) is 0.180.
- Metformin-added bovine serum nanoparticles (Met-BSA NPs) can be prepared as follows.
- Metformin was stirred for 24 hours in a micelle and aqueous solution state, and then organic solvent ethanol (EtOH) was added dropwise to obtain metformin-added bovine serum nanoparticles (Met-BSA NPs).
- the anticancer drug composition was treated with ultrasonic waves, and the remaining material was removed using a centrifugal separator. The product was freeze-dried.
- 10a is a result of analyzing micelles including anticancer drug composition formula 13 and metformin according to Preparation Examples 6 and 7 with a scanning electron microscope (SEM).
- 10B is a result of analyzing the particle size of micelles containing the anticancer drug composition Chemical Formula 13 and Metformin according to Preparation Examples 6 and 7.
- the average particle size of the anticancer composition is about 187.1 nm, and the polydispersity index (PDI) is 0.217.
- Lung cancer cell line A549 was cultured in RPMI-1640 medium containing 10% FBS and 1% penicillin-streptomycin in an incubator at 37°C and 5% CO 2 environment.
- the A549 cell line was cultured in a 24-well plate at a density of 5x10 4 cells per well for 24 hours. Thereafter, the anticancer agent compositions were dispensed so that the concentration of the photosensitizer was 1uM and incubated for 24 hours. To evaluate PDT efficacy, a 660 nm laser was irradiated at 2 joules per unit area (J/cm2) x 15 minutes, and after 24 hours, cell viability was calculated using CCK-8 (Cell Counting Kit-8).
- Preparation Example 7 (Formula 13) is a result of the PDT effect of micelles containing Metformin, one of the active oxygen species induction enhancers, different from Chemical Formula 13 according to Preparation Example 7 on cancer cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne : une composition anticancéreuse de type noyau/enveloppe renfermant un noyau comprenant un photosensibilisateur représenté par la formule chimique 1 et une enveloppe comprenant de l'albumine sérique bovine ou de l'albumine sérique humaine ; et son procédé de préparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0141334 | 2021-10-21 | ||
KR1020210141334A KR20230057188A (ko) | 2021-10-21 | 2021-10-21 | 광반응성을 이용한 복합 항암제 조성물 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023068423A1 true WO2023068423A1 (fr) | 2023-04-27 |
Family
ID=86058170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/015653 WO2023068423A1 (fr) | 2021-10-21 | 2021-11-02 | Composition de médicament anticancéreux complexe utilisant la photoréactivité et son procédé de préparation |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20230057188A (fr) |
WO (1) | WO2023068423A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090027470A (ko) * | 2007-09-12 | 2009-03-17 | 인제대학교 산학협력단 | 항암활성을 가지는 클로린 유도체 |
WO2014141289A1 (fr) * | 2013-03-12 | 2014-09-18 | Amrita Vishwa Vidyapeetham University | Composition pour photochimiothérapie à base de microcapsules à structure cœur-écorce |
-
2021
- 2021-10-21 KR KR1020210141334A patent/KR20230057188A/ko not_active Application Discontinuation
- 2021-11-02 WO PCT/KR2021/015653 patent/WO2023068423A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090027470A (ko) * | 2007-09-12 | 2009-03-17 | 인제대학교 산학협력단 | 항암활성을 가지는 클로린 유도체 |
WO2014141289A1 (fr) * | 2013-03-12 | 2014-09-18 | Amrita Vishwa Vidyapeetham University | Composition pour photochimiothérapie à base de microcapsules à structure cœur-écorce |
Non-Patent Citations (3)
Title |
---|
GALINDEV OYUNBILEG, BADRAA NARANGEREL, SHIM YOUNG KEY: "Synthesis of methyl pyropheophorbide-a pyrazole derivatives and their in vitro cell viabilities on A549 cells", JOURNAL OF PORPHYRINS AND PHTHALOCYANINES, BOGNOR REGIS, GB, vol. 11, no. 12, 1 December 2007 (2007-12-01), GB , pages 829 - 835, XP009545392, ISSN: 1088-4246, DOI: 10.1142/S1088424607000953 * |
HUANG YAN, HE NA, WANG YUNQING, SHEN DAZHONG, KANG QI, ZHAO RONGFANG, CHEN LINGXIN: "Self-assembly of nanoparticles by human serum albumin and photosensitizer for targeted near-infrared emission fluorescence imaging and effective phototherapy of cancer", JOURNAL OF MATERIALS CHEMISTRY. B, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 7, no. 7, 13 February 2019 (2019-02-13), GB , pages 1149 - 1159, XP093057791, ISSN: 2050-750X, DOI: 10.1039/C8TB03054E * |
YOON IL, LI JIA ZHU, SHIM YOUNG KEY: "Advance in Photosensitizers and Light Delivery for Photodynamic Therapy", CLINICAL ENDOSCOPY, vol. 46, no. 1, 1 January 2013 (2013-01-01), pages 7, XP093057794, ISSN: 2234-2400, DOI: 10.5946/ce.2013.46.1.7 * |
Also Published As
Publication number | Publication date |
---|---|
KR20230057188A (ko) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010126178A1 (fr) | Nouveau composé conjugué de chlore e6-acide folique, procédé de préparation de ce composé et composition pharmaceutique contenant ledit composé pour le traitement du cancer | |
KR101938800B1 (ko) | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 | |
WO2018128360A1 (fr) | Composition photothermique biocompatible pour le traitement du cancer et de maladies de la peau | |
WO2018186725A1 (fr) | Composition pharmaceutique pour le traitement du cancer | |
EP1404678B1 (fr) | Derives porphyriques hydrosolubles destines a un traitement photodynamique, leur utilisation et leur production | |
WO2013048022A2 (fr) | Nanofils de phtalocyanine de zinc de type α ayant une solubilité dans l'eau améliorée et une dispersibilité dans l'eau améliorée, composite d'un nanofil de phtalocyanine de zinc de type α/phénothiazine et procédé pour leur préparation | |
JPS625985A (ja) | 新規なテトラピロール化合物 | |
EP1137411B1 (fr) | Derives bacteriochlorophylle a substitution palladium et utilisation associee | |
EP4086268A1 (fr) | Dérivé de pyrrolobenzodiazépine et conjugué ligand-lieur associé | |
WO2010151074A2 (fr) | Conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique | |
WO2011090333A9 (fr) | Conjugués de dérivés de chlore/acides gras insaturés, photosensibilisateurs les comprenant, et compositions de traitement du cancer destinées à être utilisées dans la thérapie photodynamique comprenant lesdits conjugués | |
WO2020096318A1 (fr) | Nanoparticules de carbone sensibles au ph, leur procédé de préparation, et administration de médicament les utilisant | |
AU2002312154A1 (en) | Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture | |
WO2023287111A1 (fr) | Complexe de micelles et vecteur de médicament le comprenant | |
EP1669358A1 (fr) | Agents cytotoxiques comprenant des nouveau taxanes | |
WO2023068423A1 (fr) | Composition de médicament anticancéreux complexe utilisant la photoréactivité et son procédé de préparation | |
WO2020145790A1 (fr) | Procédé de synthèse de nanoparticules d'acide hyaluronique, et nanoparticules d'acide hyaluronique préparées par le procédé | |
WO2018131989A1 (fr) | Composition de thérapie photodynamique utilisant un gène exprimant une protéine fluorescente et un photosensibilisateur, et procédé de thérapie photodynamique utilisant cette composition | |
WO2017026578A1 (fr) | Hydrogel de chélate de chitosane pour le traitement du cancer et procédé de préparation de celui-ci, et composition pharmaceutique et composition pour embolothérapie contenant toutes deux celui-ci en tant que substance active | |
WO2010126179A1 (fr) | Composition pharmaceutique comprenant un composé conjugué de chlore e6-acide folique et du chitosane pour le traitement du cancer | |
WO2023048453A1 (fr) | Nanoparticules comprenant des dimères de médicament et leur utilisation | |
WO2021129678A1 (fr) | Conjugué avec groupe sensible au rayonnement et son utilisation | |
WO2020159080A1 (fr) | Hydrogel photoréticulable, marqué par un isotope radioactif et son procédé de préparation | |
WO2023128282A1 (fr) | Lieur bifonctionnel comprenant du métaallylsilane et son procédé de préparation | |
WO2022235040A1 (fr) | Complexe de bio-imagerie et diagnostic ou traitement de cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21961511 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |